## **Chapter 5 | Regulatory Considerations in Biotechnology (Government Engagement)**

Approval & Usage (1902-2018)154
[5.2.1] Biotech and Drug Approvals at FDA – NMEs & NBEs (1990-2019) in 5-Year Intervals156
[5.2.2] FDA Approvals – Biologics vs Drugs (1996-2015)157
[5.3] Clinical Stage Success Rates – FDA Product Approvals of Drugs versus Biologics (2010-2016)
[5.4] Product "Innovation" – NBEs & NMEs (1986-2014)158
[5.5.1] Annual New Therapeutic Product Approvals by FDA (Drug & Biotech Product NMEs & NBEs) (1999-2020)159
[5.5.2] FDA NME/NBEs vs Biotech Products, 5-Year Intervals (1996-2019)160
[5.6.1 - 5.6.11] FDA Orphan Drug Designations (2001-2020)
[5.6.1] ALL FDA Orphan Drug Designations (Drugs & Biotech; Marketed & R&D), versus Orphan Drug Designations for Marketed Products (Drugs & Biotech) (2001 - 2020)161
[5.6.2] Overall Orphan Designations, All Drugs/Molecules Vs All Biotech Molecules (2001-2020)
[5.6.3] Orphan Drug Designations (ODDs) by FDA, Summary (1983-2020)163
[5.6.4] Orphan Drug Designations – All Biotech Molecules by Therapeutic areas & Types of Products (2018 & 2019 & 2020)163
[5.6.5] Orphan Drugs Designations – Types of Biotech Marketed Products [Total = 216] (1983-2020)
[5.6.6] Orphan Drug Designations for Marketed Biotech Products by Medical Disciplines (1983-2020)
[5.6.7] Orphan Drugs Designations for Biotech Marketed Products, in 5-Year Intervals (2000-2019)

[5.6.8] New Orphan Drugs Designations for ALL Biotech Products (R&D & Marketed) (1983- 2020)166
[5.6.9] New Orphan Drug Designations per Year for Biotech Molecules/Products in Development (R&D) in 5-Year Intervals (1983-2019)167
[5.6.10] Orphan Drug Designations – Biotech Products in R&D – in 5-Year Windows (1983- 2019)168
[5.6.11] Orphan Drug Designations – All Biotech Products in R&D by Medical Disciplines (1983- 2020)169
[5.6.12] Orphan Drug Designations - Indications for Biotech Products (October 2018 Example)170
[5.7.1] FDA Breakthrough Therapy Designations (BTD), Biotech & Drugs, (2014-2020)175
[5.7.2] FDA Breakthrough Therapy Designations by Types of Products (2013-2020)176
[5.7.3] FDA Breakthrough Therapy Designations by FDA by Year from (2013-2020176
[5.7.4] FDA Breakthrough Therapy Designations for Biotech by FDA by Medical Disciplines (2013-2020)
[5.8] FDA Priority Reviews Biotech and Drug Products (2000-2020)178
[5.9] FDA Accelerated Review Designations - Biotech and Drug Products (2000-2020)179